Group led by partners Tom Meyers and Zachary Hyde joins across Boston and New York | 2d
Group led by partners Tom Meyers and Zachary Hyde joins across Boston and New York | 2d
Firm says hire underscores commitment to strengthening UK IP practice | 4d
Luke Tucker Harrison’s prognosis is good, following successful treatment | 1w
Merged firm to house 230 professionals and operate under Venner Shipley name | 2w
This second edition offers updated guidance on protecting brands against counterfeiting and the grey market, covering relevant legislation, enforcement measures and cross-border strategies in key jurisdictions around the world. | 1mo
Editor:
Healthcare deals specialist Jason Zemmel will be based in London | 1mo
The long-running IP dispute related to the Nobel Prize-winning gene editing technology CRISPR rumbles on and now extends beyond ownership, write HSF lawyers Emily Bottle and Dylan Churchill | 1mo
Plaintiff lawyer David Kessler was lead counsel in landmark Tyco class action | 1mo
Sale to US private equity firm Clayton Dubilier & Rice comes as investors anticipate more and larger European PE buyouts | 1mo
Californian court finds ‘strong likelihood’ that ex-employee took trade secret information to benefit his own company | 1mo
Latest lawsuits in mounting patent litigation over vaccines against the two viruses | 1mo
Arrival of Tim Powell continues US firm’s European IP push | 1mo
GSK’s two patents declared invalid as both attempt to launch first RSV vaccine in UK market | 1mo
Novartis and Genentech had accused Korean rival of “imminent infringement” through marketing of biosimilar | 2mos
Charles Atkinson to replace Todd Kingma, who retires from Perrigo for a second time | 3mos
Veteran IP litigator Hiroshi Sheraton and M&A lawyer Luciana Griebel join in London | 3mos
The way the request was processed still raises ‘significant concerns’, says the firm | 3mos
Alexander Klett, Christoph Mikyska and Sebastian Dexheimer move over from Reed Smith and Milbank | 4mos
Pan-European patent court delivers first revocation judgment a year and a month after opening | 4mos
Any regulatory changes to drug patents and pricing should be wary of stifling innovation, writes Neal Gerber Eisenberg lawyer Thomas Campbell | 4mos
Trio of partners join from Wilson Sonsini and boutique Hooper Lundy & Bookman as Orrick continues life sciences push | 4mos